Mylan NV on Friday said it will pay $465 million US to settle the question of whether misclassification of its EpiPen emergency allergy treatment resulted in underpayment of rebates to the U.S. Medicaid healthcare program.
from CBC | Health News http://ift.tt/2cXNNeG
ABOUT THE AUTHOR
Hello We are OddThemes, Our name came from the fact that we are UNIQUE. We specialize in designing premium looking fully customizable highly responsive blogger templates. We at OddThemes do carry a philosophy that: Nothing Is Impossible
0 commentaires:
Enregistrer un commentaire